Israel’s Beyond Air (see here previously) has partnered with US-based Beyond Cancer to produce a form of immunotherapy for solid tumors known as ultra-high concentration nitric oxide (UNO). The ultra-high concentration of UNO is undergoing Phase 1 human trials. https://nocamels.com/category/news-briefs/#post-126279

The LungFit Nitric Oxide device from Israel’s Beyond Air (see here previously) speeds up the recovery of hospitalized COVID patients. Clinical (human) trials showed they needed less oxygen support and spent less time in the hospital than those who didn’t … Continue reading →

Israel’s Beyond Air announced positive top-line results from its third pilot study in bronchiolitis patients. 89 infants under 12 months were treated at 8 sites in Israel. https://www.globenewswire.com/news-release/2020/05/20/2036389/0/en/Beyond-Air-Achieves-Primary-Endpoint-in-Pilot-Bronchiolitis-Study.html

Israel’s Beyond Air develops LungFit  – a revolutionary Nitric Oxide (NO) generator and delivery system. The US FDA and Health Canada have approved the use of LungFit in COVID-19 treatment trials in both countries. https://www.beyondair.net/news-media/press-releases/detail/101/beyond-air-to-initiate-clinical-study-evaluating-high

Israel’s Advanced Inhalation Therapies (Beyond Air) has been granted Orphan status by the US FDA to complete the development of its nitric oxide (NO) treatment for cystic fibrosis. The NO gas boosts the body’s immune system, improves blood flow and … Continue reading →

Israel’s Advanced Inhalation Therapies (Beyond Air) is to begin two clinical trials using nitric oxide (NO) to treat infectious lung diseases. Immune systems of the young are very sensitive to viral infections. Nitric oxide gas could help toddlers and infants … Continue reading →